Demcizumab

Tax included
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
MedChemExpress 
HY-P99261

Data sheet

Size
Multiple sizes
Reactivity
Notch
Application
Cancer-programmed cell death
CAS
1243262-17-0